Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 1998

View Archived Issues

Orphan Medical files NDS for Busulfex Injection in Canada

Gene Logic and P&G expand drug discovery collaboration

Diatide obtains license to key imaging-related technology from Merck & Co.

Aradigm initiates U.S. phase II studies of AERx Diabetes Management System

Novartis updates status of immunosuppressive agent

Agouron initiates human testing of antirhinoviral agent AG-7088

Liposome Co. files for approval of Evacet in U.S.

Transkaryotic Therapies initiates phase II program for Fabry's disease

NPS Pharmaceuticals updates epilepsy program

AF1 promotes optic nerve regeneration in mouse model of glaucoma

Studies using 5-ht6 antagonist Ro-04-6790 provide new clues about receptor function

Potent GH secretatogue series patented by Sumitomo

Meiji Seika describes carbapenems with potent, broad-spectrum activity

Antiarrhythmic agents in early development at Meiji Seika

MMP inhibitors synthesized and evaluated for biological activity at Hoechst Marion Roussel

Zeneca's new pain-relieving agents revealed in patent literature

Itraconazole prevents relapse of P. marneffei infection in HIV-infected patients

Another market launch for Orion's COMT inhibitor

Patent claims relating to use of Avant's TP-20 in stroke allowed

Idoxifene antagonizes estrogen effects in reproductive tissues

CP-336156 further characterized pharmacologically and pharmacokinetically at bone meeting

British Biotech discontinues marimastat monotherapy study in ovarian cancer

SciClone receives additional approvals for Zadaxin

MRI with Eovist useful for differential diagnosis of focal liver lesions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...